Use of 177 Lu-dotatate in the treatment of iodine refractory thyroid carcinomas

Oliván-Sasot, P.; Falgas-Lacueva, M.; García-Sánchez, José; Vera-Pinto, V.; Olivas-Arroyo, Consuelo; Bello-Arqués, P.

doi:10.1016/j.remnie.2016.11.007

Cited by 4 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 25%-50% of patients with locally advanced or metastatic differentiated non-medullary thyroid carcinoma (DTC) become non-responsive to RAI (2,3). Treatment options are limited, one of which is recently proposed as PRRT, and there are few cases in the literature performing this treatment option (1,(4)(5)(6). It has been reported that this treatment produces stabilization and even partial disease remission in these patients (7).…”

Section: Discussionmentioning

confidence: 99%

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

Ataei-Nakhaei

Aryana

Mostafavi

et al. 2022

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response.

show abstract

Section: Discussionmentioning

confidence: 99%

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

Ataei-Nakhaei

Aryana

Mostafavi

et al. 2022

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…Nearly 30% of patients with progressive metastatic differentiated thyroid carcinoma develop a radioiodine-refractory disease (7). Treatment options are limited in these patients (8). In asymptomatic patients as well as in stable, or minimally progressive disease, monitoring during TSH suppression is recommended (9).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?

et al. 2023

View full text Add to dashboard Cite

A 61-year-old woman with a history of metastatic follicular thyroid carcinoma became radioiodine-refractory following two doses of radioiodine (RAI) therapy (cumulative = 230 mCi). While no RAI-avid lesion was noticed in the last post-ablation whole-body radioiodine scan (WBIS), she reported sternal pain, which was accompanied by rapidly rising thyroglobulin levels. 18F-FDG and 68Ga-DOTA-TATE PET/CT was performed, showing metastatic pulmonary nodules and a lytic sternal lesion with acceptable avidity (i.e. uptake ≥ liver). Following four cycles of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-TATE, the thyroglobulin levels dropped significantly, and the sternal pain was partially alleviated. Despite only experiencing grade I thrombocytopenia, the treating physician decided to discontinue PRRT and repeat the diagnostic WBIS. Surprisingly, the scan revealed significantly increased tracer uptake in the sternum. The patient received 200 mCi 131I, and WBIS showed increased RAI uptake in all pulmonary nodules as well as bone metastases. We report a case of RAI-refractory thyroid carcinoma with a somatostatin-receptor expression that re-differentiated and gained significant RAI uptake capacity after PRRT.

show abstract

“…177 Lu-labeled or 90 Y-labeled somatostatin analogs that bind somatostatin receptors are the most common PRRT in clinical practice. 177 Lu-DOTATATE demonstrated modest efficacy of biochemical or anatomic response for RAIR-DTC patients ( 92 , 93 ). In another study of 90 Y-DOTATOC for RAIR-DTC patients (n=11), disease control was observed in 63.6% (7/11) patients (2 of PR and 5 of SD) with a duration of response of 3.5-11.5 months ( 94 ).…”

Section: Landscape Of Treatment In Dedifferentiated Thyroid Cancermentioning

confidence: 99%

Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer

Zhang

Sun

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Dedifferentiated thyroid cancer is the major cause of mortality in thyroid cancer and is difficult to treat. Hence, the essential molecular mechanisms involved in dedifferentiation should be thoroughly investigated. Several studies have explored the biomolecular modifications of dedifferentiated thyroid cancer such as DNA methylation, protein phosphorylation, acetylation, ubiquitination, and glycosylation and the new targets for radiological imaging and therapy in recent years. Novel radionuclide tracers and drugs have shown attractive potential in the early diagnosis and treatment of dedifferentiated thyroid cancer. We summarized the updated molecular mechanisms of dedifferentiation combined with early detection by molecular modification-based imaging to provide more accurate diagnosis and novel therapeutics in the management of dedifferentiated thyroid cancer.

show abstract

Use of 177 Lu-dotatate in the treatment of iodine refractory thyroid carcinomas

Cited by 4 publications

References 8 publications

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?

Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer

Contact Info

Product

Resources

About